

Checklist for Legembi (lecanemab) Referral

Patient Name:	DOB:	Date:
Referring Physician:	NPI:	:
Office Contact/Title/Email:		
Office Address:		
Office Phone:	Office Fax:	
Best contact number for physician in case of rea	action:	
Please return completed checklist and checklist in	tems to initiate referral. Use	e this form as fax cover sheet.
Patient demographic information		
Insurance information and copy of insura	ance card/s (front and back)	. *Include primary and secondary insurance
Supporting clinical notes and office visits	s. Two notes preferred.	
 Note should include any therapi 	ies tried/failed, and must inc	clude discussion about Leqembi
 Medication list and allergies 	· · · · · · · · · · · · · · · · · · ·	
 Cognitive assessment and funct Supporting lab reports/imaging for Lege 		e and interpretation
• MRI within 1 year of treatments	start	
\circ Confirmation of amyloid beta pa	athology (LP or PET Scan)	
 ApoE testing to determine ARIA 	risk	
 CMS Registration (required ever 	ry 6 months)	
Durable Power of Attorney for Health Ca	are (DPAHC), if applicable	
 Leqembi Prescribing Order (see attached Leqembi Indication Checklist (see attached 	•	

Fax all information to our Infusion Coordinator: 508-698-8671

Call with any questions: 781-551-5812 option 4



Prescribing Order: Leqembi (lecanemab)

Date of Order:	New Start Dainter Date of	nance last infusion:	
Patient Name:	DOB:	M/F:	
Diagnosis (include ICD-10 code/s):			
NKDA Allergies:			
Patient Weight:			
Premedication:			
Acetaminophen 1000mg PO	Diphenhydramine	25mg IV	
Loratadine 10mg or Cetirizine 10mg PO	Solu-medrol 125m	ng IV in 50ml over 15min	
Diphenhydramine 25mg PO	Other:		
Lab Orders:			
LEQEMBI Medication Order:			
Leqembi 10mg/kg in 250ml 0.9% Sodium 0	Chloride infused over 1 hour every 2	weeks	
Maintenance: Leqembi 10mg/kg in 250ml	0.9% Sodium Chloride infused over	1 hour every <u>4</u> weeks	
Other:			
Administration:			
	be 5^{th} 7^{th} and 14^{th} infusion then an	nually	
 ✓ Hold infusion if no MRI Brain prior to the 5th, 7th, and 14th infusion, then annually ✓ Hold infusion and notify provider if patient experiencing any of the following signs of ARIA: 			
• Headache, Confusion, Dizzine			
 In case of infusion reaction, STOP infu 	ision and follow ICNE infusion reaction	on protocol. Notify physician.	
Ordering Provider Name	NPI		
Signature	Date		



Patient	Name: DOB:			
	Legembi/Kisunla Indication Checklist			
	INFORMATION REQUIRED FOR TREATMENT INITIATION			
1)	Patient ICD-10 (select all that apply)Clinical Diagnosis (select one)G30.0 Alzheimer's disease, early onsetMild cognitive impairment due to ADG30.1 Alzheimer's disease, late onsetMild AD DementiaG30.9 Alzheimer's disease, unspecifiedMild cognitive impairment			
2)	Cognitive Screening: within 6 months Date:			
	Name of Test Used: Score: Score:			
	Interpretation:			
	Functional Screening: within 6 months Date:			
	Name of Test Used: Score: Score:			
3)	Confirmation of Amyloid-Beta Pathology: MUST provide supporting documentation			
	Amyloid PET Scan Date: Result:			
	CSF Amyloid Confirmation Date: Result:			
4)	Monitoring for Amyloid Related Imaging Abnormalities (ARIA) ***LEQEMBI/KISUNLA <u>requires</u> brain MRI within 1 year of treatment start date***			
	 Initial MRI Brain Date: Evidence of ARIA-E Negative Positive Evidence of ARIA-H Negative Positive 			
5)	Schedule for MRI Monitoring: the following is required by Infusion Center of New England			
	Leqembi: Obtain MRI prior to the 5 th , 7 th , and 14 th infusions			
	□ Kisunla: Obtain MRI prior to the 2 nd , 3 rd , 4 th , and 7 th infusions			
6) 7)	 6) Is the patient on anticoagulation? Yes 7) Is the patient on antiplatelets? Yes No 			
8)	Has ApoE testing been performed? Ves No			
- /	Result:			
9)	CMS REGISTRATION NUMBER			
	(REQUIRED) Date:			